API Quick Links: http://en.hichipharm.com/

+86-152-0110-8103 yanglm@beilupharma.com

EN

EN
jp
fr
de
es
ru
pt
ar

- English
- 日本語
- français
- Deutsch
- Español
- русский
- português
- العربية

Hichi Pharmaceutical's Iodixanol API Approved for Market

2024/09/09

/uploads/image/2024/09/06/contrast-media-products-20240906-1.jpg

Iodixanol is the active pharmaceutical ingredient for iodixanol injection, a contrast agent used for intrathecal contrast, cardiovascular angiography, and intravenous urography. Its mechanism of action involves the absorption of X-rays by iodine in blood vessels or tissues, resulting in image display.

This time, Hichi Pharmaceutical's iodixanol active pharmaceutical ingredient obtained the "Chemical Active Pharmaceutical Ingredient Marketing Authorization Approval Notice." This not only enriches Hichi Pharmaceutical's active pharmaceutical ingredient variety and enhances its market competitiveness but also promotes the steady growth of Hichi Pharmaceutical's API sales business. Additionally, it will expand the depth and breadth of the company's integration of APIs and formulations in the field of contrast agents, creating favorable conditions for expanding the company's competitive advantage and market share in the contrast agent field.

References

Related Products

Gadopentetate Dimeglumine Injection/API

Gadopentetate Dimeglumine Injection/API

Traditional Chinese Medicine-Jiuweizhenxin Granules

Traditional Chinese Medicine-Jiuweizhenxin Granules

Related News

Beilu Pharmaceutical's Gadoterate Meglumine Injection Win the Bid for the 10th National Drug Centralized Procurement
December 17, 2024On December 12, 2024, Beilu Pharmaceutical participated in the bidding process for the 10th National Drug Centralized Procurement organized by the National Joint Drug Procurement Office. Beilu Pharmac...view
Beilu Pharmaceutical Wins Emerging Pharmaceutical Internationalization Award at CPHI China
June 26, 2025CPHI & PMEC China 2025 recently made a grand debut in Shanghai. This year's exhibition showcases the latest innovations and cutting-edge technologies across the entire pharmaceutical supply ch...view
Frequently Asked Questions about Iodine Contrast Users (3)
May 13, 20211. Does the iodinated contrast agent need to be preheated? Can the patient benefit from it?Preheating the iodinated contrast agent before use is recognized as the best method of application.view
Beilu Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Indian Registration Certificate
July 25, 2025Recently, Zhejiang Hichi Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received the Iodixanol API product registration certificate issued by the Central Drugs Stand...view
Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.
September 21, 2023Beilu Pharmaceutical's subsidiary, Zhejiang Hichi Pharmaceutical, has recently obtained the certificate of registration for Iohexol API from the Ministry of Food and Drug Safety in Korea.This regi...view
Jiuwei Zhenxin Granules - Independent Innovation, Classic Inheritance
February 24, 2021A famous traditional prescription in Song Dynasty passed down for thousands of years.view

Call us on:
+86-152-0110-8103
Email Us:
yanglm@beilupharma.com
No.3 Shuiyuan West Road, Miyun District, Beijing, China

Sitemap | Privacy Policy
Copyright © Beijing Beilu Pharmaceutical Co., Ltd. All Rights Reserved.

+86-152-0110-8103